Diasorin | DIA

Stock Price
82.34
Daily Change
-0.22 -0.27%
Monthly
-1.27%
Yearly
-18.60%
Q3 Forecast
81.67

Peers Price Chg Day Year Date
Amplifon 15.28 0.19 1.23% -45.41% Sep/05
Avanos Medical 12.72 0.06 0.47% -46.37% Sep/05
Brookdale Senior Living 7.69 0.04 0.52% 14.26% Sep/05
Cencora 292.50 -0.20 -0.07% 24.33% Sep/05
Diasorin 82.34 -0.22 -0.27% -18.60% Sep/05
Encompass Health 125.58 1.10 0.88% 37.01% Sep/05
Enovis 32.13 0.58 1.84% -26.04% Sep/05
GE HealthCare Technologies 75.73 1.61 2.17% -11.00% Sep/05
OPKO Health 455.00 -6.10 -1.32% -21.85% Sep/07
Zimmer Biomet Holdings 105.73 0.97 0.93% 0.76% Sep/05

Indexes Price Day Year Date
IT40 41608 -381.90 -0.91% 24.98% Sep/05
EU600 549 -0.88 -0.16% 8.42% Sep/05

Diasorin traded at 82.34 this Friday September 5th, decreasing 0.22 or 0.27 percent since the previous trading session. Looking back, over the last four weeks, Diasorin lost 1.27 percent. Over the last 12 months, its price fell by 18.60 percent. Looking ahead, we forecast Diasorin to be priced at 81.67 by the end of this quarter and at 79.70 in one year, according to Trading Economics global macro models projections and analysts expectations.

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.